What are the pathways for an Rx to OTC switch?

• A. Submit Supplemental NDA
• B. Petition FDA
• C. Amend drug Monograph
• D. All of the above

Answer: (D)

Switching a prescription drug to OTC can be pursued through multiple regulatory routes, depending on how the drug is positioned with respect to OTC standards and monographs.

A supplemental NDA can be filed to change a product’s status from prescription to OTC and to update its labeling and indications accordingly. This route is common when the sponsor has data showing the product can be safely used by consumers without a prescriber oversight and when an immediate switch is desired outside of the monograph framework.

A petition to the FDA is a formal mechanism to request regulatory action, such as initiating or accelerating switch processes or amending the monograph. It allows interested parties to advocate for a status change or labeling changes, prompting FDA consideration and rulemaking where appropriate.

Amending the drug monograph is another route. If an OTC monograph already covers the product or can be amended to include it, products that conform to the monograph’s requirements can be marketed OTC without a separate approval. This pathway is used when there’s enough consensus or precedent to fit the drug into an established OTC framework.

Because each pathway is a valid route to achieve OTC status depending on the drug’s situation, all of these routes can be used to accomplish the Rx-to-OTC switch.